Long-Acting Injectable Therapy for People with HIV: Looking Ahead with Lessons from Psychiatry and Addiction Medicine

By sjmartinez • November 29, 2022

Edwards GG, Miyashita-Ochoa A, Castillo EG, Goodman-Meza D, Kalofonos I, Landovitz RJ, Leibowitz AA, Pulsipher C, El Sayed E, Shoptaw S, Shover CL, Tabajonda M, Yang YS, Harawa NT. Long-Acting Injectable Therapy for People with HIV: Looking Ahead with Lessons from Psychiatry and Addiction Medicine. AIDS Behav. 2022 Sep 5:1–15. doi: 10.1007/s10461-022-03817-z. Epub ahead of print. PMID: 36063243; PMCID: PMC9443641.

Tags: Addiction medicine, Antiretroviral medication, Cost, HIV treatment, Implementation barriers and facilitators, Infectious Diseases, Long acting injectable medication, Psychiatry, Publications

Related Posts

Integration of HIV pre-exposure prophylaxis (PrEP) services for pregnant and breastfeeding women in eight primary care clinics: results of an implementation science study

Nelson A, Bheemraj K, Dean SS, de Voux A, Hlatshwayo L, Mvududu R, Berkowitz N, Neumuller C, Jacobs S, Fourie S, Coates T, Gail-Bekker L,[...]

How I Do It: Managing Cavitary Coccidioidomycosis Expert Opinions for Improving Patient Outcomes

Donovan FM, Thompson GR 3rd, Blair JE, Johnson RH, Malo J, Albasha W, Worrell SG, Beamer SE, Yaddanapudi K, Galgiani JN, Ampel NM. How I[...]

Safety, tolerability, pharmacokinetics, and neutralisation activities of the anti-HIV-1 monoclonal antibody PGT121.414.LS administered alone and in combination with VRC07-523LS in adults without HIV in the USA (HVTN 136/HPTN 092): a first-in-human, open-label, randomised controlled phase 1 trial

Edupuganti S, Hurt CB, Stephenson KE, Huang Y, Paez CA, Yu C, Yen C, Hanscom B, He Z, Miner MD, Gamble T, Heptinstall J, Seaton[...]